New RDC No. 1,011 expands regulatory details on Cannabis derivatives, medicinal products, and pharmaceutical inputs

Pharmaceutical entities challenge in the Supreme Court the exclusivity of hospitals in dispensing magistral formulas based on medicinal cannabis, as provided in a recent decree

Revision of RDC 327 allows the compounding sector to produce derivatives, while individual importation by individuals remains under old rules and will be analyzed separately

Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate

New resolution allows planting by universities and pharmaceutical industries, requiring maximum security systems and total traceability of the plant

Proposal aims to regulate the performance of non-profit entities in a controlled experimental environment, using the Regulatory Sandbox model to comply with STJ decision

Lecture led by specialist will address scientific updates, clinical use, and regulation of cannabinoid therapies in Dentistry during the event in São Paulo

Patient follow-up for up to two years

Resumption of review by Anvisa and final deadline from STJ for cultivation define the sector's direction in the first quarter of the year

The Spanish Supreme Court has accepted the request from pharmaceutical entities challenging the exclusivity of dispensing cannabis products only in hospitals, as determined by the recent Royal Decree

Process could determine whether the genetics will be classified as a genetically modified organism or treated as a conventional plant in Brazil

Located in the South Pacific, New Caledonia has presented a legislative proposal to structure a regulated tropical hemp sector by 2030, with rules for cultivation, processing, and sanitary control

A group of 58 specialists from public and private universities advocates for evidence-based regulations for the cultivation and regulation of cannabis in Brazil

Expectation is that the president will issue an executive order transferring the plant to Schedule III; measure would facilitate research and banking access after cannabis reclassification

Experts warn about the irregular use of zolpidem and discuss medical cannabis as a safer alternative for treating sleep disorders

The regulatory agency published the decision in the Official Gazette of the Union this Monday (8), allowing the inclusion of the dosage of 300 mg/ml

Proposal in the review of RDC 327/2019 to RDC 660/2022 divides opinions and raises doubts about access and judicialization

The submission of scientific evidence is essential to support the regulation of cannabis cultivation in Brazil and complies with STJ's determination

Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence

Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence